Ionis Pharmaceuticals Inc (IONS)vsMerck & Company Inc (MRK)
IONS
Ionis Pharmaceuticals Inc
$74.48
-0.87%
HEALTHCARE · Cap: $12.11B
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 6115% more annual revenue ($65.77B vs $1.06B). MRK leads profitability with a 13.6% profit margin vs -30.9%. MRK appears more attractively valued with a PEG of 5.36. MRK earns a higher WallStSmart Score of 50/100 (D+).
IONS
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$165.82
Current Price
$74.48
$91.34 discount
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 87.0% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Trading at 25.2x book value
ROE of -66.5% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IONS
The strongest argument for IONS centers on Revenue Growth. Revenue growth of 87.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : IONS
The primary concerns for IONS are Piotroski F-Score, PEG Ratio, Price/Book. Debt-to-equity of 4.15 is elevated, increasing financial risk.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
IONS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
IONS carries more volatility with a beta of 0.37 — expect wider price swings.
IONS is growing revenue faster at 87.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). IONS offers better value entry with a 49.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ionis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?